slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,578
Current window 99,061-99,090
Pages 3,953
Rows per page 30
Component
99,061-99,090 of 118,578
57
Uses a simple input-process-output flow to demystify LLM inference.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
58
The slide uses a simple input-process-output flow to demystify LLM inference.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
59
Uses a central block to represent the Transformer architecture as a black-box processor.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
60
The slide uses a simple input-process-output flow to demystify LLM inference.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
67
The chart illustrates the divergence between traditional CPU scaling and the accelerated growth enabled by AI and specialized hardware.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
74
Includes code snippets as decorative background elements.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
76
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
81
The slide uses a dot plot to show binding affinity vs sequence diversity and a bar chart to compare binding rates.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
82
The slide shows two dose-response curves (Cell Surface Binding and ADCC) and two molecular surface models for epitope mapping.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
86
The slide uses molecular visualization of RBD mutations and a table showing KD (binding affinity) values, highlighting the poor binding (607 nM) to the beta variant.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
87
The slide uses a two-step process flow (1 and 2) to explain the technical methodology of their AI-driven drug discovery platform.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
88
The slide uses a process flow (1 -> 2) followed by a scatter plot validation and a summary table of Pearson R values.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
89
SPR stands for Surface Plasmon Resonance. The charts show binding affinity (KD) comparisons.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
93
Includes pseudo-code snippets in the background.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
94
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
105
The slide illustrates a scientific workflow for target discovery.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
106
The chart shows a dose-dependent increase in absorbance for ABS-301 compared to isotype controls, suggesting binding/inhibition activity.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
107
The slide uses a combination of a horizontal bar chart and a data table to quantify the addressable market.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
01
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
05
The chart plots UC maintenance remission rates against maintenance dosing frequency, showing current standard-of-care drugs clustered at lower efficacy and higher frequency, while the 'Spyre Target' is positioned at higher efficacy and lower frequency.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide features a stylized antibody graphic overlaid on a dark blue/purple abstract background.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
14
The slide uses a comparative bar chart approach to justify the human half-life prediction based on NHP data.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
28
The slide uses a biological process diagram to illustrate the mechanism of action for three distinct therapeutic assets.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
34
The slide uses a timeline-like structure to map clinical catalysts against expected timeframes.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
01
The slide features a split design with a white left side containing logos and a dark purple abstract background on the right.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
04
The slide uses a three-column layout to compare product candidates.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Situation & Context1 hit
08
The slide uses a split-screen layout with a photo of a person on the right and branding on the left.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
12
The slide outlines a standard clinical trial progression for SAD and MAD cohorts, including randomization ratios and participant types.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
22
The slide uses a funnel diagram to illustrate the selection process from initial discovery sets to final candidate properties.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
01
The logo features negative space silhouettes of a person and a dog within the letters.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · What Is1 hit